Bayer buys Algeta

Share this article:

Bayer is ponying up $2.9 billion to buy now-former oncology partner Algeta, reports PMLive. The deal means Bayer will own the prostate cancer therapy Xofigo outright.

The company previously estimated the alpha-particle-emitting therapeutic agent would hit $1.3 billion in annual sales.

The FDA approved the treatment in May.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.